Bionorica Selects Veeva CRM to Improve Commercial Execution Globally
Veeva Systems (NYSE:VEEV) today announced that Bionorica SE, a fast-growing German manufacturer of herbal medicines, has selected multichannel Veeva CRM to streamline business processes and improve customer interactions globally. The company has also adopted Veeva OpenData in Russia for reliable, complete customer data to help field teams deliver more focused interactions with healthcare professionals (HCPs).
“We previously relied on multiple systems and needed a CRM solution that was quick to implement and easy to use. Veeva CRM gives us a proven industry application that we are able to deploy with speed to drive more efficient and effective engagement with HCPs and pharmacies,” said Christian Kunzelmann, head of IT at Bionorica. “With Veeva CRM, we have a complete view of all customer touchpoints which enables us to be more nimble and deliver truly tailored customer engagement.”
Veeva CRM is the industry’s leading platform for organizations of all sizes, from pre-commercial launching their first product to the largest global biopharma companies. Advanced mobility, multichannel capabilities, and real-time insights enable field teams to drive effective customer engagement across all channels, including face-to-face, email, and web. With Veeva CRM, Bionorica can now engage with the right customer in the right channel at the right time.
“In addition to our implementation of Veeva CRM, we selected Veeva OpenData in Russia to empower our teams with high quality customer data,” said Thomas Hansch, head of global sales at Bionorica. “With Veeva OpenData, our sales force teams have real-time access to accurate customer information to target customers more effectively and improve commercial execution.”
Veeva OpenData provides access to approximately 16 million HCPs and their healthcare organizations spanning 100 countries, including data partnerships. Combined with multichannel Veeva CRM, field teams have the most accurate information to engage with the right customer in the right channel at the right time.
Veeva CRM and Veeva OpenData are part of Veeva Commercial Cloud. Learn how Veeva Commercial Cloud enables intelligent customer engagement at the upcoming Veeva Commercial & Medical Summit Europe, 3-5 December, in Barcelona. The event is open to Veeva customers and invited guests. Register and view the agenda at veeva.com/eu/summit.
Additional Information
For more on multichannel Veeva CRM, visit: veeva.com/eu/CRM
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 775 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2019. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191121005072/en/
Contact information
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors22.10.2025 03:25:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) for the development, manufacturing and commercialization of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China.* IBI363 is being evaluated in non-small cell lung and colorectal cancers and has shown potential efficacy in additional solid tumor types. IBI343 is being evaluated in gastric and pancreatic cancers. Takeda will also receive an exclusive option to license global rights outside of Greater China for IBI3001, an early-stage investigational medicine. “IBI363 and IBI343, two next-generation investigational medicines, have the potential to address critical treatment gaps for patients with a range of solid tumors,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “We are energized by the progress made by Innovent to date and look forward to collaborating to unlock the potential of t
YES Selected to Deliver Full Portfolio of Advanced Packaging Tools for Glass Panel AI and HPC Applications by a Leading AI Infrastructure Supplier21.10.2025 22:16:00 EEST | Press release
Yield Engineering Systems (YES), a leading provider of advanced process equipment for AI and high-performance computing (HPC) semiconductor applications, today announced that it has received multiple tool orders from a global leader in AI infrastructure solutions. The orders span YES’s portfolio of Dry and Wet process systems and will support panel-level manufacturing on glass substrates for next-generation data center and HPC packaging. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020459437/en/ YES VertaCure, VertaPrime, VeroFlex, TersOra, and SURE systems. The systems will be deployed in advanced packaging lines dedicated to hyperscale AI workloads, including training, inference, networking, and co-packaged optics. This award marks a significant milestone in the industry's shift toward glass-based 2.5D and 3D packaging as system performance, density, and thermal requirements escalate. YES will supply a full suite of s
Esri and UNFPA Extend Strategic Partnership to Support 2030 Census Round21.10.2025 22:09:00 EEST | Press release
Esri, the global leader in location intelligence, today announced the extension of its strategic partnership with the United Nations Population Fund (UNFPA) in support of the 2030 census round. Building on a successful collaboration during the 2020 census round, the partnership aims to embed geographic information system (GIS) technology into all phases of census work. By leveraging GIS, national statistics and census offices will gain access to more authoritative, location-enabled data and faster, more efficient methods of planning, collection, and dissemination. “National census projects can often involve mapping an entire country,” said Linda Peters, Esri global business development manager. “GIS is becoming crucial for every step of a census but deploying it is new to many national statistical offices. We are happy to provide the resources that can enable this large-scale feat of authoritative data collection and communication.” The integration of location intelligence into census
AXS and Lawson Entertainment Partner to Enhance Fan Ticketing Experiences in Japan21.10.2025 21:41:00 EEST | Press release
AXS, the trusted leader in advanced ticketing and live event technology, today announced the establishment of AXS Tickets, a new joint venture with Lawson Entertainment, one of Japan’s leading entertainment and ticketing companies, marking a major expansion of AXS’s business in Japan. This partnership builds on AXS’s successful presence in Japan, combining AXS’s world-class technology and global expertise with Lawson Entertainment’s (Lawson Tickets’) deep industry relationships and highly recognized consumer brand. Together, they aim to expand access to live entertainment and sports across Japan. Since its launch in 2018, AXS Japan has powered ticketing for thousands of events and sold tens of millions of tickets for some of the country’s fastest-growing sports leagues, professional teams, and major event organizers. The creation of AXS Tickets strengthens that foundation — enabling AXS and Lawson Entertainment to deliver a new level of innovation and scale for artists, promoters, venu
ChipAgents Raises Oversubscribed $21M Series A to Redefine AI for Chip Design21.10.2025 17:30:00 EEST | Press release
Today ChipAgents, the agentic AI platform transforming chip design and verification, announced the close of a $21 million Series A funding round, bringing the total fundraise to $24 million to date. This latest round closed with Bessemer Venture Partners, with strategic backing from Micron, MediaTek, Ericsson, and additional top semiconductor companies. Also participating in the round are notable angels including new advisors, Wally Rhines, Raúl Camposano,and Jack Harding, and existing support by ScOp Venture Capital (Ivan Bercovich) and Amino Capital, fueling the company’s expansion of product development, customer acquisition, and strategic industry partnerships. ChipAgents’ mission is to bring the power of AI to the heart of chip design and verification. Every engineer should be empowered with tools that make the most complex aspects of hardware development faster, more intuitive, and dramatically more productive. Chips are the foundation of our digital world, yet the process of bui
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom